ABSTRACT ISIS 104838, a 2'-O-methoxyethyl (2'-MOE)-modified antisense oligonucleotide (ASO), causes a moderate, reproducible, dosedependent, but selflimiting decrease in platelet (PLT) counts in monkeys and humans. To determine the etiology of PLT decrease in cynomolgus monkeys, a 12-week repeat dose toxicology study in 5 cynomolgus monkeys given subcutaneous injections of ISIS 104838 (30-60 mg/kg/week). Monkeys were also injected intravenously with 111 Indium(In)-oxine-labeled PLTs to investigate PLT sequestration. In response to continued dosing, PLT counts were decreased by 50%-90% by day 30 in all monkeys. PLT decreases were accompanied by 2-to 4.5-fold increases in immunoglobulin M(IgM), which were typified by a 2-to 5-fold increase in antiplatelet factor 4 (antiPF4) IgM and antiPLT IgM, respectively. Monocyte chemotactic protein 1 increased upon dosing of ISIS 104838, concomitant with a 2-to 6-fold increase in monocyte-derived extracellular vesicles (EVs), indicating monocyte activation but not PLT activation. Despite a 2-to 3-fold increase in von Willebrand factor antigen in all monkeys following ASO administration, only 2 monkeys showed a 2-to 4-fold increase in endothelial EVs. Additionally, a $60 -80%% increase in PLT sequestration in liver and spleen was also observed. Collectively, these results suggest the overall increase in total IgM, antiPLT IgM and/or antiPF4 IgM, in concert with monocyte activation contributed to increased PLT sequestration in spleen and liver, leading to decreased PLTs in peripheral blood.
and low-grade systemic inflammation. Clinical chemistry parameters are typically within normal limits following 2 0 -MOE ASO treatment, but when changes are observed, they are often secondary to the class effects described earlier.
In the case of hematology parameters, dose-dependent changes in platelet (PLT) counts have been observed following treatment in cynomolgus monkeys for some 2 0 -MOE ASOs (Henry et al., 2017) . Drawing from collective observations made in toxicology studies of various durations in monkeys, 2 basic phenotypes of PLT changes have emerged (Henry et al., 2017) . Phenotype 1 is a consistent, reproducible (for a given ASO), moderate and selflimiting degree of PLT decline occurring over a course of at least 4-6 weeks of treatment. Animals presenting with this phenotype have PLT counts that are reduced from baseline by approximately 30%-50% in a dose-dependent fashion, but achieve a new "steady-state" level that generally remains within the normal range with continued treatment (!150 K cells/ml). This phenotype has been observed in monkeys with approximately 40% of evaluated 2 0 -MOE ASO's and thus appears to be sequence-specific.
Phenotype 2 is sporadic and associated with more severe decreases in PLTs that can affect overall hemostasis. Phenotype 2 can present as either moderate or severe declines in PLTs (ie, PLT count between 75 and 200 K cells/ll) or severe (ie, PLT count <50 K cells/ll), and is often not reproducible between studies with the same 2 0 -MOE ASO (Henry et al., 2017) . Despite low incidence of phenotype 2, the incidence appears to be dose-dependent. Decreases in PLT count have occasionally been observed in clinical trials with 2 0 -MOE ASOs , but they are generally easily monitored, reversible on pausing or discontinuation of treatment and/or administration of steroids. In the general human experience, there have been 3 of 16 2 0 -MOE ASOs that have been associated with PLT declines like Phenotype 1 described in monkeys, but severe thrombocytopenia has been relatively rare. The notable exception to this was a low incidence of severe thrombocytopenia reported in phase 3 trial for familial chylomicronemia syndrome and mutant transthyretin amyloidosis patient populations . Because of the relatively mild decrease, the apparent sequence-dependent nature of this change and dose dependence, the implications of reduced PLT count are relatively limited; however, the recent occurrence of more clinically significant thrombocytopenia in some human patient populations warrants a thorough evaluation and a better understanding of the potential mechanism(s) involved. Thrombocytopenia is a recognized side effect of treatment with a wide range of medications (Aster et al., 2009) . Even though most of these medications lower PLT levels by accelerating clearance through immune and (less often) nonimmune mechanisms (Aster, 2006; Aster and George, 2006 ), a few preferentially inhibit megakaryocytopoiesis to produce isolated thrombocytopenia. In nonclinical studies, unexpected thrombocytopenia associated with therapeutic monoclonal antibodies (mAb) has been infrequently reported. Acute in onset, these are often due to direct PLT activation (Curtis et al., 2002; Santostefano et al., 2012) , or caused by hemophagocytic syndrome, where activated macrophages phagocytose normal PLTs (Everds et al., 2013) . Unlike the acute drop in PLT levels often seen in mAb-induced thrombocytopenia, decreases in PLT count observed in monkeys treated with 2 0 -MOE ASOs do not occur acutely after first exposure, but rather, are gradual and associated with repeated administration. Phenotype 1 lends itself to further mechanistic investigation since it is sequence-specific (ISIS 104838), reproducible and its potential translatability to the clinic Kwoh, 2007) . ISIS 104838, a 2'-MOE ASO targeting human tumor necrosis factor-a (TNF-a) mRNA, which was tested in several toxicology studies, up to 9 months in duration, in cynomolgus monkeys (not pharmacologically active in this species) serves as a tool compound to further investigate mechanisms of Phenotype I (Henry et al., 2007; Shen et al., 2016) . Across multiple studies, this sequence has produced a decline in PLT count consistent with Phenotype 1. Occasionally, cynomolgus monkeys have also exhibited the more severe drops consistent with Phenotype 2.
To prospectively assess the potential for ISIS 104838 to induce PLT activation and/or alter serum biomarkers reflecting immune-mediated changes, 5 cynomolgus monkeys were treated with a loading dose of 30 mg/kg/wk ISIS 104838 subcutaneously (SC) on days 1, 4, and 7 followed by twice weekly dosing of 30 mg/kg to produce moderate reductions in PLTs.
MATERIALS AND METHODS
This study and related analyses were not conducted in compliance with the Food and Drug Administration Good Laboratory Practice regulations for Nonclinical Laboratory Studies; however, applicable standard operating procedures and sound scientific practices were followed.
Chemical and Reagents
ISIS 104838 is a 20-nucleotide PS ASO with the sequence GCTGATTAGAGAGAGGTCCC, and it comprises five 2 0 -MOE ribonucleosides at the 3 0 -and 5 0 -ends (as indicated by underline) with 2 0 -deoxynucleosides in between. All cytosines are 5-methyl cytosine. ISIS 104838 was designed to target human TNF-a mRNA and is not biologically active in monkeys (Ionis, internal data). ISIS 104838 was synthesized at Ionis Pharmaceuticals, Inc.
(Carlsbad, California). The ASO was purified by reverse-phase high-performance liquid chromatography and formulated in phosphate-buffered saline (PBS) at a concentration of 100 mg/ml.
Animals
The study was conducted at an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited facility that has an Animal Welfare Assurance issued by the Office of Laboratory Animal Welfare (OLAW), is registered with the United States Department of Agriculture (USDA), and has an Institutional Animal Care and Use Committee (IACUC) that is responsible for compliance with applicable laws and regulations regarding the use of laboratory animals. Five female cynomolgus monkeys of Chinese origin (age 4-6-years old) were individually housed in a temperature-and humidity controlled environment, providing a 12-h light/dark cycle. Animals were fed twice daily with ad libitum access to water. The study protocol was approved by IACUC at the Testing Facility prior to dose administration.
Study Design
Five cynomolgus monkeys were given a loading dose of 30 mg/kg/week ISIS 104838 (SC) on days 1, 4, and 7 followed by 30 mg/kg twice weekly dosing up to day 38 (days 10, 14, 17, 21, 24, 28, 31, and 35) , and then once weekly dosing thereafter (days 38, 45, 52, 59, 66, 73, and 80 In-oxyquinoline labeled PLTs to study PLT sequestration. In addition, assessment of total serum immunoglobulins (Igs), antiPF4 and antiPLT antibodies, chemokines/ cytokines, thrombopoietin (TPO), von Willebrand Factor (VWF), ADAMTS13, flow cytometric detection of PLT-derived extracellular vesicles (EVs) along with routine clinical pathology were also performed prior to treatment and at several time points throughout the study. In vitro PLT stimulation (detection of CD62P upregulation by flow cytometry), was also performed separately in PLT rich plasma (PRP) to rule out direct activation of PLTs by ISIS 104838.
PLT Sequestration Using 111
In-oxine-Labeled PLTs Autologous PLT isolation and 111
In-oxine radiolabeling. PLT isolation began with the peripheral blood draw from the saphenous vein with approximately 1 ml blood collected into a red-top tube (no additive) and discarded, followed by 21.6 ml blood collected into 4 tubes containing 3.2% sodium citrate. Each tube was immediately inverted gently 3-4 times to ensure mixing. All PLT isolation tubes were maintained at room temperature (RT). PLTs were isolated from PRP by high speed (1200 Â g) centrifugation and resuspended in saline containing anticoagulant citrate dextrose solution-formula A (ACD/A) with 1 mM prostaglandin E1 and PLT poor plasma (PPP). 350-550 mCi
111
In-oxine was added to the PLT sample, followed by gentle mixing and incubation at RT for 20 min. PLTs were then centrifuged and the pellet and supernatant counted in dose calibrator. The PLT pellet was resuspended in 2 ml PPP and a 50 ml sample taken for CD62P: CD61 flow cytometry analysis. The labeled PLT in PPP is the injectate. As soon as flow cytometry results were obtained (within 20 min) the PLTs were injected into donor monkey.
Image acquisition. Each animal served as its own negative control (NC) since PLT sequestration was assessed prestudy (day -8). Monkeys were anesthetized with an intramuscular injection of Ketamine at a dose of 10 mg/kg prior to being placed on the gamma camera patient gantry in the supine position. Then, each monkey was slowly injected with the autologous PLT injectate, over 1-min, via a saphenous vein catheter. PLT injectate contained between 170 and 200 mCi In-oxine. Dynamic image acquisition was performed on an ADAC gamma camera in 3 segments beginning 5-15 s prior to PLT injection. The image segments were 1 s Â 60 frames, 4 s Â 225 frames, 300 s Â 8 frames with a 64 Â 64 matrix and 111 (In)-oxine dual peak window. All image files were saved to the picture archiving and communications system (PACS) in digital imaging and communications in medicine (DICOM) format prior to analysis.
Static images were acquired 24-h post-PLT injection as a 512 Â 512 matrix with a minimum 200 000 count total. All image files were saved to the PACS in DICOM format prior to analysis. For all imaging, a medium energy general purpose (MEGP) collimator was used.
Image analysis methodology. Mean region of interest (ROIM) has defined dimension (circle) that is placed within the organ region of highest activity. The ROIM provides the best means of tracking time-activity during dynamic imaging and is used to calculate the 111 In-PLT activity ratios of liver/heart and spleen/heart. Heart and liver had homogeneous In-PLT distribution while distribution in the spleen was more heterogeneous with much of activity in the head of the spleen and less in the "tail".
Organ ROI is the approximate dimensions of each organ as defined as counts per pixel above background tissue 111 In-PLT activity, and is used to calculate the % of injected dose (%ID) and standard uptake value (SUV) bw for the 24-h time point static imaging. The %ID was calculated from whole organ ROI activity divided by total 111 In input activity from 24-h time point static images times 100. The %ID is corrected for 111 In decay and time 0 input 111 In-PLT dose. Whole body % ID cannot be determined from the data as 12%-15% of the body is outside the image area. SUVbw is the SUV based on body weight and is calculated as the mean ROI activity/cm 2 divided by the whole monkey input activity/body weight in grams.
Flow Cytometry Assay for Detection of PLT Drug-Dependent Antibodies Briefly, serum samples were tested for drug-dependent and nondrug-dependent PLT antibodies by flow cytometry, based on methods published elsewhere (Curtis, 2014) . Fresh human group O PLTs (1 Â 10 7 /well) from a single random blood donor were incubated with 40 ml of monkey sera and 25 ml of either ISIS 104838 (0.5 mg/ml; 68.6 mM) or PBS. PLTs incubated with serum and ISIS 104838 and were then washed with buffer containing drug (0.5 mg/ml). PLTs incubated with serum and PBS were then washed in PBS alone. PLT-bound Igs were then detected with fluorescent labeled antihuman IgG and antihuman IgM. PLT-bound IgG and IgM fluorescence intensity was determined by flow cytometry. Fluorescence ratio (FLR) values were calculated for each sample by dividing median fluorescence intensity (MFI) in presence of drug by MFI without drug. For human serum samples, FLR > 1.5 is considered positive for drug-dependent antibodies. Nondrug-dependent PLT antibodies were determined by dividing MFI without drug present by MFI of normal human serum control. FLR ! 2.0 was considered positive. This assay utilized human PLTs for testing cynomolgus monkey serum samples because of logistical issues involved in obtaining fresh monkey PLTs.
Heparin-Platelet factor 4 (PF4) ELISA for Detection of HeparinDependent Antibodies The PF4 ELISA was based on a previously described proprietary kit that detects antibodies of 3 Ig classes (IgG/A/M) against PF4/ polyvinyl sulfonate complexes (Visentin et al., 2001) . For IgG/A/M, a confirmatory high-concentration heparin step was performed concurrently, in which 100 U/ml (high dose) of unfractionated porcine heparin (UFH) was added to the patient's sample. Monkey serum samples were diluted to 1:50 in PBS (pH 7.4) prior to being tested.). Briefly, monkey sera were incubated in duplicate with complexes of polyvinylsulfonate (PVS) and PF4 (PVS-PF4) in 2 separate wells of a microtiter plate. It is well established that PVS is equivalent to UFH when complexed with PF4 for detection of heparin-dependent antiPF4 antibodies in human sera (Murugesan et al., 2008) . Unfractionated heparin UFH of 100 U/ml was added to the second well as a confirmatory step. Each well was washed, incubated with alkalinephosphatase labeled antihuman IgG or IgA or IgM, washed again, and bound antibody detected by addition of phosphatase substrate and optical density (OD) measurement by spectrophotometry. Sera from patients with heparin-induced thrombocytopenia (HIT) typically give IgG OD values > 1.0 were used as positive controls. Only PF4-IgG and PF4-IgM were detectable in this study. Note: this assay was not validated for use in testing nonhuman primate serum samples.
Measurement of Plasma EVs
Plasma EVs were analyzed by vesicle flow cytometry (VFC) using a fluorogenic membrane probe to stain EVs for detection and size measurement, and fluorescent antibodies to measure EV surface antigen expression (Brooks et al., 2017; Stoner et al., 2016) . Briefly, plasma was diluted 1:800 in 0.025 lm filtered 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) PBS, stained with membrane dye and fluorescent antibodies/ligands (10 nM each, final, Supplementary Table 1) for 1 h at ambient temperature, and diluted a further 1000-fold. Samples were analyzed with a Beckman Coulter CytoFlex flow cytometer with the violet side scatter (VSSC) filter configuration, using the blue (488 nm) excited red fluorescence (690/50 nm band pass) of the membrane probe to trigger detection. EVs were gated on their red fluorescence and VSSC (Supplementary Table 1 ) and the total EV concentration in plasma estimated by accounting for the volume of sample measured and all dilutions during sample processing. EV size distribution was estimated using a synthetic vesicle standard (liposome) whose size distribution was determined by nanoparticle tracking analysis. Marker positive EVs were determined by setting a threshold on signal from EVs without surface marker added. Fluorescence intensities are expressed in units of mean equivalent soluble fluorochromes for labels for which calibration standards were available (FITC, APC: Bangs Laboratories; PE: BD Biosciences), otherwise fluorescence intensity is expressed in arbitrary units.
Measurement of Serum Biomarkers
Multiplex cytokine analysis was performed on serum samples from all animals, by using a panel that has known crossreactivity with cynomolgus monkeys, using Milliplex panel kits (EMD Millipore, Billerica, Massachusetts) and a Luminex FlexMAP 3D instrument with the XPonent version 4.0 software. Thawed serum samples were assessed for the following cytokines/chemokines: granulocyte macrophage-colony stimulating factor (GM-CSF), interferon gamma (IFN-c), IFN-a, interleukin 1b (IL-1b), IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p40, IL-13, IL-17A, IL-21, IL-22, monocyte chemoattractant protein-1 (MCP-1), TNF-a, and human recombinant TPO. VWF antigen was detected using ELISA developed at Blood Center Wisconsin Hemostasis Laboratory using capture antibodies developed in their hybridoma lab and polyclonal antibodies from appropriate vendor. ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin repeats, number 13) activity was confirmed in plasma samples using fluorescence resonance energy transfer (FRET) with a synthetic substrate, FRETS-VWF73 as per previously published methods described elsewhere (Kokame et al., 2005) , but with 10 ll of citrated plasma per 500 ll total assay volume. A 0-8 ml cynomolgus monkey control plasma was aliquoted for assay standards, and 4 ml of each test plasma sample was diluted in 100 ml of assay buffer (5 mmol/l Bis-Tris, 25 mmol/l CaCl 2 , 0.005% Tween-20, pH 6.0) in a 96-well white plate (Biotek). Then, 100 ml of 4 mmol/l FRETS-VWF73, prepared in buffer, was added to each well. Fluorescence was measured at 30 C by a Wallac 1420 ARVO multilabel counter (Biotek) equipped with a 340-nm excitation filter and a 450-nm emission filter. Fluorescence was measured every 5 min. The reaction rate was calculated by linear regression analysis of fluorescence over time from 0 to 60 min using the prism software (GraphPad Software, San Diego, California).
In Vitro Measurement of PLT Activation Whole blood samples from 3 naïve monkeys (performed at SNBL, Everett, USA) were centrifuged at 170 Â g for 15 min without braking. PRP was collected from the top layer and used for PLT activation experiments. PLTs were resuspended in modified HEPES-Tyrode's buffer (10 mM HEPES, 137 mM NaCl, 2.8 mM KCl, 1 mM MgCl 2 , 12 mM NaHCO 3 , 0.4 mM Na 2 HPO 4 , 0.35% [w/v] bovine serum albumin (BSA), 5.5 mM glucose, pH 7.4) in a volume equal to original PRP volume. The control or test articles included various concentrations of ISIS 104838 and ISIS 120704 (0.1-100 mM), 5 mM 4-phorbol 12-myristate 13-acetate (PMA), 5 and 20 mM ADP as positive controls. ISIS 120704 is a CpG containing nonMOE ASO. CpG containing oligonucleotides with a PS backbone can activate PLTs directly (Flierl et al., 2015) . Control or test articles were added to 20 ml whole blood in a final volume of 25 ml and incubated for 20 min at RT. After incubation, antiCD41a-APC (for identification of PLTs) and antiCD62P-PE (for assessment of activation), diluted in modified Tyrode-HEPES buffer, were added, each at 10 mg/ml final concentration, and incubated for 20 min at RT. Lyse/fixative solution (400 ml; 2% formalin, 10 mM HEPES, 0.15 mM NaCl, pH 7.4) was added to each sample and samples were stored at 4 C until analyzed by flow cytometry (FACSCalibur, BecktonDickinson). PLTs were identified by gating on CD41aþve events and excluding events with low forward scatter to remove PLTderived EVs. Activated PLTs were identified by an increase in MFI of CD62P compared with resting PLTs. Data were analyzed using FlowJo software (v.7.3, Treestar, Ashland, Oregon).
Estimation of Various IgM Antibodies
Chemiluminescent ELISA was performed to measure specific IgM antibody levels in monkey serum as previously described in Binder et al. (2003) and Gonen et al. (2014) . Briefly, antigen (malondialdehyde-modified Low-density lipoprotein [MDA-LDL], copper sulfate-oxidized LDL (Cu-Ox-LDL), phosphocholineconjugated PC-BSA, a-1, 3-Dextran) at concentration of 5 lg/ml was added to wells of white, U-bottom microplates (Phenix Research, Candler, North Carolina) and incubated overnight at 4 C. Then, the plate was blocked with 1% BSA in Tris-buffered saline for 60 min at RT, and incubated with diluted monkey plasma (for a-1, 3-Dextran IgM plates 1:100; for MDA-LDL, Cu-Ox-LD and PC-BSA IgM plates: 1:200) for 90 min at RT. Alkaline phosphatase (AP) conjugated goat antihuman IgM (l-chain specific) (Sigma Chemical Company, St Louis, Missouri) was used for detecting the binding. Lumi-Phos 530 (Lumigen, Southfield, Michigan) was used to detect the AP-conjugated secondary antibody. The resulting light emission was measured by Synergy HTX (BioTek, Winooski, Vermont) as relative light units counted per 100 ms (RLU/100 ms).
Anti-Drug Antibody (ADA) Assay in Monkey Plasma
An ELISA method was developed by Ionis Pharmaceuticals, Inc.
(Carlsbad, California) to detect antibodies directed against specific 2 0 MOE ASOs in monkey serum or plasma. A plate specific screening cut point was generated using the 95th percentile (1.0837*mean of NC OD values) from drug-naive individual monkey serum (Shankar et al., 2008) . If the sample OD was ! the plate specific screening cut point, then the sample was considered screen positive. The screen positive samples were further evaluated in a confirmatory assay, where serum samples were preincubated with and without ISIS 104838. If the sample OD inhibition was ! 12.8%, then the sample was confirmed positive for ADA. If the inhibition was < 12.8%, then the sample was report as negative. Additional titration assays were performed on samples which were confirmed positive for ADA using similar procedures as the screen assay, except the titration cut-point generated using the 99.9th percentile. Final titers were reported as the highest dilution factor ! the plate specific titration cut point (1.1542 Â Mean of NC OD values), multiplied by the minimum required dilution (50) (Supplementary Table 2 ).
Bone Marrow Hematoxylin and Eosin Staining in Monkey
The sternum was collected during the comprehensive necropsy of a thrombocytopenic monkey (PLT 75 K cells/ll [phenotype 2]) that had been treated with a related 2 0 -MOE ASO to ISIS-104838. The sternebrae were split open with a scalpel to facilitate fixative penetration. The tissue was fixed in 10% neutral buffered formalin, decalcified, embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin for examination by light microscopy (Supplementary Figure 1) .
Statistics
Any statistical test used herein excluded animal No. G432.
Comparisons of in vivo data between 2 time points (baseline and post-treatment) were analyzed with a paired Student's t-test.
Multiple comparisons were evaluated with 1-way analysis of variance (ANOVA), followed by a post hoc Dunnett's test with JMP version 13 (SAS Institute). A p < .05 was considered significant.
RESULTS

PLT Counts and MPV
All 5 animals had reduced PLT counts by day 30 compared with their predose baselines (baseline counts ranged from 396 to 551 K cells/ml) (Figs. 1A and C). In total 4 of the 5 animals showed the moderate PLT decline typically observed with this 2 0 -MOE ASO, achieving a 50% decrease which was maintained at approximately 150 K cells/ml with continued treatment. Animal No. G432 exhibited a more severe drop in PLT count consistent with Phenotype 2, the more sporadic decrease in PLT counts described previously. This animal developed thrombocytopenia (78 K cells/ml) by day 16 (after 5 doses). PLT counts in this animal recovered after an initial dosing holiday on days 35 and 38 to approximately 140 K cells/ml on day 44, but values declined again upon resumption of dosing to 16 K cells/ml. PLT counts returned to baseline levels upon a combination of dosing holidays (days 59 and 66) and corticosteroid (Depo-Medrol, 80 mg/first week, 40 mg/second week) treatment, on days 64 and 71, but returned to 51 K cells/ml day 86 upon continued dosing. Mean PLT volume (MPV) increased the most for Animal No. G432, indicating intact megakaryocyte function in response to the demand of increased peripheral PLT clearance ( Figure 1B) . The PLT reduction in monkeys was not due to ADAs as all monkeys were negative for the presence of anti-ISIS 104838 antibodies (Supplementary  Table 2 ), apart from Animal 119-124C, which was weakly positive on days 72 and 84. As corticosteroid treatment is an established treatment for immune-mediated thrombocytopenia, this study was also designed to assess the response to corticosteroid intervention once PLT counts decreased. All 5 monkeys were treated with 80 mg Depo-Medrol on day 64 followed by a dose of 40 mg on day 71. In general, PLT counts in Animal Nos. 082494, 119-124C, MF44550F, and G419, showed little if any response to corticosteroid treatment ( Figure 1A ). Corticosteroid treatment was notably more effective in Animal No. G432, who was the only animal with a PLT count <50 K cells/ml, consistent with our experience from other monkey studies (Ionis internal unpublished data). As PLT counts increased, MPV also returned to normal in this animal, suggesting an immune-mediated nature of the thrombocytopenia. The effectiveness of continuous corticosteroid treatment was not examined in this investigation.
PLT Sequestration Imaging
Prior to the start of the study, 9 female monkeys were assessed for the level of naïve PLT activation (CD62P activation by flow cytometry) and 5 monkeys were selected for the study. The screen was intended to identify and exclude animals that may have high intrinsic levels of PLT activation that could interfere with the sequestration results. Additionally, to avoid injection of activated PLTs during the process of 111
In-oxine labeling, samples were screened for expression of CD62P. All injectates on days -8 and 55 sequestration analysis met the screen criteria-lack of CD62P upregulation on PLT surface.
Dynamic imaging of the animals was conducted prestudy on day -8. and during day 55 of the dosing phase. Acquisition of dynamic imaging began 5-15 s prior to injection of autologous In-PLT counts in liver and spleen were normalized to heart and expressed as liver/heart or spleen/heart ratios, since heart is not considered as an organ for PLT sequestration (Figure 2A ). PLT sequestration observed in the liver and spleen during dynamic imaging on day 55 was markedly different in most animals compared with their respective baselines. Animal No. MF44550F showed marked PLT sequestration in spleen, but not in liver, within 1-h postdose on day 55 compared with day -8. Animal No. G432 showed a dramatic increase in liver PLT sequestration as well as a moderate increase in spleen, over an approximately 1-h time course, on day 55. PLT sequestration in liver and spleen were also evident in Animal Nos. 119-124C and G419, with splenic sequestration in both these animals. Animal No. 082494 had only a transient shift to slightly higher sequestration in the spleen over the first 15 min on day 55 compared with baseline.
At 24-h postday 55 injection (day 56), an overall increase in PLT sequestration (an average of 60 -80% increase over day -7) in liver and/or spleen was evident in all 5 monkeys, as measured by the % of injected dose, which corrects for 111 In decay ( Figure 2B ). Comparing the results from the dynamic imaging to the 24-h postdose static imaging, the rapid splenic sequestration seen in Animal No. MF44550F within the first hour post PLT injection (day 55) only translated into a mild sustained increase in 111 In-PLT sequestration 24-h postdose. Animal No. G432 showed a consistent and marked increase in liver sequestration at both 1 (day 55) and 24-h postPLT injection (day 56) compared with the baseline; however, PLT sequestration in spleen at 24 h was minimal. Amongst the animals that showed a mild increase in PLT sequestration in spleen and/or liver (Animal Nos. 082494, 119-124C, and G419), Animal No. 082494 demonstrated the least amount of PLT sequestration within 1-h postdose on day 55. The SUV adjusted by body weight was also calculated and showed comparable results (Data not shown).
In Vitro PLT Activation PLT activation was investigated using flow cytometry and PLTs from 3 additional cynomolgus monkeys to address the potential contribution of direct PLT activation by ISIS 104838. A concentration-dependent increase in CD62P upregulation was observed with ADP and PMA as expected. For both PMA and ADP, the response from all 3 monkeys was more or less equivalent. However, there was no increase in CD62P expression on monkey PLTs with ISIS 104838 at concentrations from 0.1 to 100 mM. Thus, ISIS 104838 did not directly activate PLTs at concentrations up to 50-fold plasma C max at therapeutically relevant doses of 300 mg in human with SC administration (approximately 4.3 mg/kg in a 70-kg subject; Yu et al., 2013) (Figure 3 ).
Role for Activation of Monocytes and Endothelial Cells in ImmuneMediated Thrombocytopenia
In this study, serum chemistry and cytokine/chemokine panels were evaluated at multiple time points to further assess the nonspecific proinflammatory effects of ISIS 104838. The growth factor, cytokine and chemokine panel included GM-CSF, TPO, IFN-c, IFN-a, TNF-a, MCP-1, IL1-b, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL17A, IL21, and IL22 measured at baseline and multiple time points during treatment.
One of the most interesting findings was that the decrease in IL-8 levels from basal levels paralleled the PLT decrease and was very pronounced in all monkeys with thrombocytopenia (Figures 4A). Monkeys normally have high basal levels of IL-8 (He et al., 2014) . Interestingly, as PLT counts returned to baseline levels in Animal No. G432, IL-8 rebounded to normal levels as well. In animals where PLTs were consistently down, IL-8 did not show return to baseline levels. The recovery to basal levels of IL-8 was also seen in 2 other monkeys. Overall, IL-8 levels correlated with PLT levels (r ¼ 0.52; p > .05) ( Figure 4B ). Besides IL-8, only MCP-1 showed approximately 2-to 9-fold increase, which occurred in all monkeys ( Figure 4C ). MCP-1 almost doubled in Animal No. G432 and showed elevation in Animal Nos. G419 and 82494. An increase in MCP-1 is consistent with the known 
Total Serum IgM and IgG
Increases in total serum Igs, relative to baseline, were noted by day 30 and were maintained in most cases with continued dosing. Total serum IgM showed a 2-to 4.5-fold increase in all monkeys, with most notable changes observed in Animal Nos. 119-124C and M44550F ( Figure 5 ). Total serum IgG was increased ! 1.5 to 3-fold, relative to baseline values. While elevated from baseline, these serum IgG levels were near the upper range of normal. Only Animal No. 119-124C showed a progressive increase in total serum IgG that was well above the normal range.
AntiPF4 Antibodies
AntiPF4 testing was performed to determine if monkeys exposed to ISIS 104838 developed antibodies against PF4 complexes. A recent report suggested that nucleic acids may form multimolecular complexes with PF4 to generate new epitopes that will bind polyanion-specific antibodies and activate PLTs (Jaax et al., 2013) . Therefore, monkey sera were tested by ELISA for IgG and IgM antibodies reactive with PVS-PF4 complexes. Assessment of antiPF4 IgG showed little to no tendency to increase in ASO-treated animals ( but returned to baseline levels for all remaining time points, so this was considered variability in the assay. Furthermore, a result was considered positive if the OD value was greater than 0.40, in accordance with both the manufacturer's instructions and the FDA-approved cut-off value. To ensure the assay was not missing a positive signal based on using PVS as the polyanion, these samples were also tested in a modified method using PF4-ASO complex coated plates and the results were similarly negative for antiPF4 IgG (Data not shown). Therefore, there was no evidence to implicate a classical IgG antiPF4 HIT-type mechanism. Interestingly, the strong increase in total IgM was accompanied by an increase in antiPF4 IgM. It should be noted that there was detectable PF4 cross-reactive IgM in these animals at baseline, which further increased with ISIS 104838 administration. An approximately 2-to 5-fold increase in antiPF4 IgM antibody levels from baseline, with the increase more pronounced in Animal No. 119-124C, was seen in all ISIS 104838-treated monkeys. However, Animal No. G432, which entered the study with a higher baseline level of antiPF4 IgM compared with other animals in the study, did not register much change in antiPF4 IgM. The 2-fold increases in antiPF4 IgM in Animal No. G419 was likely blunted by administration of corticosteroids on days 64 and 71. Animal No. G432, who had high basal level of antiPF4 IgM antibodies, was also more responsive to corticosteroid administration.
AntiPLT Antibodies
The effect of ISIS 104838-treatment on antiPLT antibody levels was also evaluated. Like observations made earlier with antiPF4 antibodies, there were detectable levels of drug-independent antiPLT antibodies at baseline that varied among the animals, and appeared to increase with ISIS 104838 treatment (Figure 7) . AntiPLT IgM was increased 2-to 3-fold from baseline in all animals and paralleled PLT count decreases. The antiPLT IgG baseline and response was more variable, with very minor change in Animal Nos. G419 and MF44550F and a progressive increase in Animal No. 119-124C. The binding of these antiPLT antibodies to PLTs were not drug dependent (data not shown). Notably, Animal No. G432 had higher basal antiPLT IgG level, and further increased during treatment. Elevated levels of antiPLT IgG in this animal could explain the more severe effect on PLT count.
These results helped formulate a working hypothesis that these increases in antiPLT IgG/IgM and/or antiPF4 IgM are secondary to innate immune cell activation lead to increased PLT clearance (Semple and Provan, 2012) . There was no increase in drug-dependent antiPLT antibodies in the presence of ISIS 104838 (Data not shown).
EVs by Flow Cytometry
To examine the propensity of ISIS 104838 to activate PLTs, evaluation for PLT-derived EVs was performed by a nanoparticle flow cytometer. PLT EVs were differentiated from monocyte and endothelial EVs based on their distinctive membrane antigens and light scatter properties by nanoparticle flow cytometry (Stoner et al., 2016) . Marker-positive EVs were determined using a fluorescent conjugated antibody cocktail consisting of PLT markers (CD61-phycoerythrin [PE] and CD41-allophycocyanin þve PLT-derived EVs.
Estimation of Various IgM Antibodies
Soluble PRRs such as naturally occurring IgMs (Chou et al., 2009; Leibundgut et al., 2013) , bind to a variety of DAMPs and PAMPs to provide homeostasis. These include, nucleotides, polysaccharides, oxidation-specific epitopes (OSEs: eg, MDA-LDL, CuOxLDL), bacteria-specific antigens (eg, PC-BSA, a-1, 3-Dextran) and advanced glycation end products (Frescas et al., 2017) . Innate immune responses: increase in total IgM (Figure 5 ), antiPF4 IgM ( Figure 6 ) and antiPLT IgM (Figure 7 ) production along with monocyte activation, observed in this study, prompted us to cast a wider net to understand the extent to which titers of innate IgM to MDA-LDL, Cu-OxLDL, PC-BSA, and a-1, 3-Dextran production was influenced by ISIS 104838 administration. All animals showed a robust response to a-1, 3-Dextran during the treatment period, with IgM levels registering a 2.6-to 7.4-fold increase in RLUs as early as day 9 (Figure 9 and Supplementary Figure 2) . Alternatively, the IgM response to PC-BSA was comparatively weak, with high background levels noted in Animal Nos. 119-124 C and G432. The maximum response was noted in Animal No. MF44550F, with a 2-fold increase in IgM to PC-BSA on day 86. Levels of MDA-LDL and antiCu-OxLDL IgM antibody levels were consistently higher in Animal Nos. 119-124C and MF44550F on day 86, with a linear (6-fold) increase in MDA-LDL and Cu-OxLDL levels from baseline levels. It must be noted that these animals also recorded higher total IgM levels during treatment with ISIS 104838, compared with other animals, which showed a 2-to 3-fold increase in MDA-LDL and -Cu-OxLDL IgM levels akin to their IgM response.
VWF and ADAMTS13
Previous repeat dose toxicology studies in monkeys demonstrated an increase in VWF (Shen et al., 2016) beginning day 85, following chronic treatment (30 mg/kg/week, s.c.) with ISIS 104838. The purpose of VWF estimation in the current study was not only to assess reproducibility of this finding at earlier time points (eg, day 30). A 2-to 3-fold increase in VWF antigen was observed in monkeys after treatment with ISIS 104838 (Figure 10 and Supplementary Figure 3) . These changes were mostly comparable across the ISIS 104838-treated animals, and occurred early (days 30 and 48) in all animals. VWF antigen levels in Animal No. MF44550F, which had higher baseline levels of VWF antigen compared with others, peaked at a later day. Increased VWF antigen levels can be due to endothelial activation following deposition of immune complexes onto the endothelial layer of the vascular wall. It should be borne in mind that circulating plasma VWF is primarily a result of endothelial release, not PLT release (Yau et al., 2015) . PLT VWF consists of primarily large and ultralarge molecular weight multimers. If there was substantial PLT activation, this could potentially be detected in the assay as "larger than normal" multimers. Increased VWF multimer formation leads to systemic clumping of PLTs often resulting in PLT counts below 20 K cells/ml, especially during an acute episode of thrombotic thrombocytopenia purpura (Moake, 2002) . Increased VWF multimer formation was not assessed in this study due to paucity of samples; however, ADAMTS13 activity was measured. Increased VWF multimer formation can lead to a prothrombotic environment resulting from diminished proteolysis of VWF by ADAMTS13. VWF is cleaved by the plasma metalloprotease ADAMTS13, which regulates the hemostatic activity of VWF by limiting its multimeric size in the human system. In vitro and ex vivo studies have shown that cynomolgus monkey ADAMTS13 is able to cleave human rVWF (Muchitsch et al., 2010) . The increased VWF antigen levels seen in monkeys treated with ISIS 104838 were not due to inhibition of ADAMTS13, as no clear decrease in ADAMTS13 activity was observed in this study. 
DISCUSSION
ISIS 104838 is representative of a subset of a 2 0 -MOE 5-10-5
gapmer ASOs that are known to produce a consistent and reproducible decrease in PLT count from baseline at doses !10 mg/kg/week (Henry et al., 2007 (Henry et al., , 2017 Kwoh, 2007) . Several toxicology studies, with ISIS 104838, have demonstrated normal bone marrow megakaryocyte morphology ( Supplementary  Figure 1) , cell density and maturation, and a lack of effect on various PLT growth factor (eg, TPO, GCSF, and GM-CSF) (unpublished observations). Normal functioning megakaryocytes are also evident by the increases in MPV, when PLT counts drop below 75 K/mm 3 essentially ruling out an effect on bone marrow function. Microangiopathy, thrombosis/disseminated intravascular coagulation can also be ruled out since there are no histologic changes indicative of clotting and lack of correlated changes in plasma fibrinogen levels. Splenomegaly is also an unlikely cause of low PLT counts since the organ weight in monkeys is typically not increased at the time when PLT counts are decreased. Although a direct role for 2 0 -MOE ASO-mediated complement activation is unlikely, persistent and/or repeated complement activation could contribute to some of the clearance mechanisms hypothesized below. All 5 ISIS 104838-treated monkeys in this study showed decreased PLT counts, compared with baseline, at a weekly dose of 60 mg/kg. In 4 of the 5 monkeys, the decrease of approximately 50% was as expected based on previous studies (phenotype 1). Animal No. G432, with a PLT count 50 K cells/ll, appeared to represent the more severe and sporadic thrombocytopenia that has been described (phenotype 2) and affords the opportunity to understand the mechanism for this phenotype as well. The low PLT count in all cases was attributed to peripheral clearance, based on increased sequestration of labeled PLTs into spleen and liver compared with baseline.
The increased peripheral clearance does not appear to be attributed to PLT activation. Specifically, direct exposure of monkey PLTs to ISIS 104838, in vitro, did not significantly increase surface expression of the PLT activation marker, CD62P, even at high concentrations (100 mg/ml or >500-fold clinical C max ). In vivo, no apparent increase in PLT-derived EVs occurred concomitant to PLT count decrease, except in Animal No. G419, ruling out PLT activation as a causative factor for low PLT counts. This is in sharp contrast to recent findings that PS oligodeoxynucleotides can cause direct PLT activation depending on ASO length and number of PS in the backbone of the molecule (Flierl et al., 2015; Sewing et al., 2017) .
Collectively, the data reported here suggest that the mechanism of decreased PLT count is most likely due to increased phagocytosis of normal PLTs by activated macrophages (Everds et al., 2013) , resulting from activation of innate immunity evidenced by increased presence of chemokines (IL-8 and MCP-1) along with increased total serum IgM, both hallmarks of oligonucleotide mediated processes (Shirakawa et al., 2010; Tasker and Marshall-Clarke, 2003) . Consequently, methods were developed to assess immune-mediated mechanisms of PLT clearance. Results show the presence of antiPLT IgM and antiPF4 IgM antibodies, coupled with presence of antiPLT IgG antibodies, favors an environment leading to migration, phagocytosis of opsonized PLTs by tissue macrophages prompting sequestration of PLTs in the spleen and liver. All samples were negative for antiISIS 104838 antibodies at the time of PLT decline in this study, ruling out ADAs as a probable cause.
Results from the current investigation have also largely ruled out a HIT-like mechanism. HIT is a well-described phenomenon that results from antiPF4 IgG binding to a novel epitope that is formed between heparin and PF4 (Greinacher and Delcea, 2015) . The hallmark of this syndrome is a 50 to 80% decline in PLT count, along with prothrombotic state caused by the PLT activation after a short, 7-to 10-day course of heparin (Greinacher and Delcea, 2015) . It is known that 2 0 -MOE ASOs are polyanionic molecules, and do bind to PF4, which has been reported previously for other RNA and DNA oligonucleotides (Jaax et al., 2013) . However, based on the general absence of antiPF4 IgG antibodies, 2 0 -MOE ASO binding does not appear to cause conformational changes in PF4 necessary to generate an antiIgG response. Analyses performed in the current study included use of both PF4-PVS and PF4-ASO complexes as antigens (Data not shown), the levels of antiPF4 IgG in monkey plasma were mostly low and well below the cut point for positivity in the human assay (OD:0.4) (Curtis, 2014) . Nevertheless, it is important to understand that there is a known prevalence of antiPF4 antibodies in humans, and presumably nonhuman primate populations, possibly based on previous exposure to bacteria and other pathogens (Krauel et al., 2011) . The preponderance of evidence now points to an apparent increase in antiPF4 IgM and/or antiPLT IgM as a part of a polyclonal antibody response that could increase rate of PLT clearance after treatment, based on increased levels of total IgM. The hypothesis that innate IgM antibodies were being induced by ISIS 104838 was further pursued by evaluating levels of other innate IgM antibodies (eg, a1, 3-dextran, PC-BSA, MDA, Ox-LDL) (Binder et al., 2016) . Although results were variable between monkeys, levels of most of these antibodies followed a similar pattern to total IgM, antiPF4/antiPLT IgM, in that titers were and OSEs (eg, MDA-LDL, Cu-OxLDL) were evaluated in monkeys treated with ISIS 104838 using chemiluminescent ELISA assays. Individual data from each monkey were plotted. Figure 10 . Increased VWF antigen levels observed in ISIS 104838 treated monkeys were not due to the inhibition of ADAMTS13 activity. VWF antigen (top panel) was detected using an ELISA assay and ADAMTS13 activity (bottom panel) was measured using FRETS-VWF73 substrate. Individual data from each monkey were plotted.
